Clinical Trials Logo

Antibiotic Reaction clinical trials

View clinical trials related to Antibiotic Reaction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05260554 Completed - Cystitis Clinical Trials

Effect of Cranberry Extract on the Urinary System

Start date: January 26, 2022
Phase:
Study type: Observational

In this study, we will try to emphasize the effects of using cranberry tablets, which is an alternative to antibiotic therapy, during uncomplicated urinary tract infections (only urinary tract, bladder and kidney infections did not).

NCT ID: NCT04409769 Completed - Clinical trials for Bone and Joint Infection

Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI

Start date: February 1, 2020
Phase:
Study type: Observational

Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.

NCT ID: NCT04196387 Completed - Antibiotic Reaction Clinical Trials

Antimicrobial Resistance Rate In Escherichia Coli And Klebsiella Pneumonia : A Retrospective Study

Start date: January 1, 2017
Phase:
Study type: Observational

Antibiotics are medicines used to avoid and treat bacterial infections. Antibiotic resistance is increasing to dangerous level globally.

NCT ID: NCT04187755 Completed - Leukemia Clinical Trials

Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever

Start date: March 1, 2019
Phase: Phase 4
Study type: Interventional

Empirical antibiotic therapy has been known to reduce the mortality and morbidity rate in neutropenic fever. Until now, ceftazidime was the first line choice of neutropenic fever. However, resistance against ceftazidime has been reported. Several countries have reported cefepime in reducing fever and shorten the length of hospitalization better than ceftazidime. This study is aimed to compare the effectivity of ceftazidime and cefepime to reduce fever and to increase the absolute neutrophils count (ANC) in the first 72 hours.

NCT ID: NCT03848104 Completed - Clinical trials for Bone and Joint Infection

Evaluation of the Use of Cefoxitin in Combination in Continuous Parenteral Administration in the Treatment of Bone and Joint Infections

Start date: January 1, 2018
Phase:
Study type: Observational

Cephamycin related to 2nd generation cephalosporins, the use of cefoxitin has long been limited to antibiotic prophylaxis. Because of its spectrum (sensitive staphylococci, enterobacteria including ESBL, streptococci, anaerobes), its stability and its low cost, it could be useful in curative bone and joint infections, especially in case of infection polymicrobial disease in patients for whom antibiotic alternative per os is limited.